

## Moderated Poster Session 5: Laparoscopy/Robotics & Stones/ Endourology Friday, November 14, 2014 3:15 – 4:30 p.m.

### P61

#### Use of Firefly Fluorescence Imaging Technology for Robotic-assisted Partial Cystectomy and Ureteral Reconstruction

Alejandro R. Rodriguez.

Samaritan Medical Center, Watertown, NY, USA.

**Background:** Firefly fluorescence imaging technology has been used during robotic assisted urological procedures, commonly for partial nephrectomies. In this study, we report on the use of this technology for robotic assisted partial cystectomy for bladder tumors and ureteral reconstructive procedures.

**Methods:** Firefly fluorescence imaging technology has been used since November 2012 at our institution. It has been used most commonly for robotic assisted partial nephrectomies. We have applied this technology during partial cystectomies and ureteral reconstructive procedures. During these procedures we either do a flexible cystoscopy (for a partial cystectomy) or a flexible ureteroscopy (for ureteral reconstruction). Once the lesion is identified, we point at it endourologically, and turn-on the Firefly technology on the robotic console. This technique allows us to visualize the endoscopic light in green color, and identify the exact point where the lesion is located. Patient demographics, perioperative outcomes and complications were analyzed.

**Results:** 2 patients were performed using this technique. In one case, the patient (61 y.o. male, BMI of 31) had a double right ureteral stricture above the iliac vessels that had been dilated and stented multiple times. A flexible ureteroscopy was used to identify the areas of stricture. Firefly technology was used to define where the resection of the ureter was going to be performed. For this case, a robotic assisted boari flap was performed. Robotic console time was 170 min, estimated blood loss was 50 cc, hospital stay was 3 days, and JP drain time was 2 days. In the second case, the patient had a bladder tumor in the dome compatible with either a bladder adenocarcinoma versus a urachal cyst remnant. A flexible cystoscopy was performed during the robotic assisted partial cystectomy plus urachal resection. Robotic console time was 80 min, estimated blood loss was 25 cc, hospital stay was 2 days, and JP drain time was 2 days. Clear cut borders of resection were identified during both procedures. At 3 months (mean time) followup, there was no complications.

**Conclusions:** Firefly fluorescence imaging technology to assist in localizing a lesion in the bladder or the ureter, proved to be effective during both the robotic assisted partial cystectomy and the ureteral reconstruction.

### P62

#### Robot-assisted Laparoscopic Simple Prostatectomy in patients with a Pathologic Specimen Weight >100 grams: A Multi-institutional Study of Outcomes

Vineet Agrawal<sup>1</sup>, Claudia Berrondo<sup>1</sup>, Anees Fazili<sup>1</sup>, Hani Rashid<sup>1</sup>, Guan Wu<sup>1</sup>, Laurence Donahue<sup>2</sup>, Jean Joseph<sup>1</sup>.

<sup>1</sup>University of Rochester Medical Center, Rochester, NY, USA, <sup>2</sup>Rochester General Hospital, Rochester, NY, USA.

**Background:** Since its first description in 2008, only 150 cases of robot assisted simple prostatectomy (RASP) have been reported in the literature for large symptomatic benign prostatic hyperplasia. Several published series of RASP have reported small average gland weight on pathological examination, where endoscopic management could have been used with equal

effectiveness, and less morbidity. We report on our experience performing RASP on patients with prostate weight of 100 grams or more.

**Methods:** Charts of patients undergoing RASP between 2009 and 2013 were retrospectively reviewed. Twenty-five patients with prostate weight >100 g as per the pathology report, were treated with RASP for BPH by four surgeons at two institutions. Both the extra- and transperitoneal approach were utilized to perform a retropubic (Millin's), or suprapubic (Freyer) prostatectomy.

**Results:** The mean age, BMI and prostate weight on histology were 73 yrs., 28 kg/m<sup>2</sup> and 136 grams respectively. The median operative time was 223 mins while the EBL was 350 ccs. The average LOS was 3.6 days. 2 patients had cystolithotomy while 1 had inguinal hernia repair concurrently. 2 patients were found to have low risk prostate cancer. The Foley catheter was removed after a mean of 10 days with leak on cystogram requiring delayed removal in 1 patient. There were three and two Clavien grade 1 and 2 complications respectively. At a mean follow-up of 20 months, all patients reported a good outcome based on symptom resolution.

**Conclusions:** Our study has shown that robot-assisted simple prostatectomy in very large prostates has acceptable perioperative outcomes and leads to successful resolution of patient symptoms.

### P63

#### Renal Nephrometry Score and Predictors of Outcomes in Laparoscopic Partial Nephrectomies

Deepak K. Pruthi, Darrel E. Drachenberg, Thomas B. McGregor.  
University of Manitoba, Winnipeg, MB, Canada.

**Background:** Nephron-sparing surgery is becoming the preferred method of managing small renal masses. Feasibility of this approach extends beyond clinical tumor size and includes anatomical complexity of the tumor. In this study we analyze patient characteristics and anatomic tumor factors to look for variables associated with surgical complications and outcomes after laparoscopic partial nephrectomy.

**Methods:** We retrospectively reviewed all patients who underwent partial nephrectomy at our academic institution between January 1, 2012 and April 30, 2014. Follow-up extended to first outpatient clinic visit 8 weeks postoperatively. All preoperative imaging was reviewed and the R.E.N.A.L. Nephrometry score (radius for tumor size as maximal diameter, exophytic/endophytic tumor properties, nearness of deepest portion of tumor to collecting system or sinus, anterior/posterior descriptor and location relative to polar line) was applied to each scan. Standardized grading systems were applied to data and standard statistical analysis to examine associations.

**Results:** Of the 102 patients who underwent partial nephrectomy seventeen (17%) patients had 19 complications; eight were Clavien-Dindo grade 3 to 4. Two patients had laparoscopic partial nephrectomies converted intraoperatively to radical nephrectomies; two other laparoscopic partial nephrectomies were converted to open partial nephrectomies. Fifty-one (50%) of operated patients were either obese, morbidly obese, or super obese. Nineteen (19%) of patients had pathologic benign lesions. Six (6%) patients had positive margins; Renal Nephrometry score was not correlated with positive margin status ( $p=0.612$ ). In univariate analysis Charlson comorbidity score ([[[Unsupported Character - Codename &shy;]]>4  $p=0.0055$ ), diabetes (47%  $p=0.0046$ ) were associated with complications while BMI >30 trended toward increased complications ( $p=0.0693$ ). However, age

(>60  $p=0.461$ ) and total R.E.N.A.L. Nephrometry score ( $p=0.286$ ) were not associated with complications. A history of anticoagulation trended toward increased risk of postoperative bleeding (22%,  $p=0.087$ ). Warm ischemic time did not vary significantly by Nephrometry score (low 27.8 min [SD  $\pm 10.0$ ], intermediate 28.8 min [SD  $\pm 9.8$ ], high 27.8 min [SD  $\pm 9.9$ ]).

**Conclusions:** Utilization of standardized reporting may be necessary for treatment decision making and the R.E.N.A.L. Nephrometry Score is a reproducible classification system that quantitates the salient anatomy of renal masses. However, as demonstrated in this laparoscopic series, categorizing renal masses according to nephrometry score did not significantly predict complication rates or expected WITs. Patient factors, however, appear to play a larger role in the development of complications.

## P64 WITHDRAWN

## P65 Extraperitoneal Robot-assisted Radical Prostatectomy in the Morbidly Obese: A Propensity Score Matched Study

Vineet Agrawal, Changyong Feng, Jean Joseph.

University of Rochester Medical Center, Rochester, NY, USA.

**Background:** An increasing number of obese patients [body mass index (BMI)  $>30$  kg/m<sup>2</sup>] with localized prostate cancer are presenting as candidates for robot-assisted radical prostatectomy (RARP), which can be carried out using the transperitoneal (TP) or the extraperitoneal (EP) approach. It has been postulated that the EP approach may offer advantages in the obese. Morbidly obese (BMI  $>40$  kg/m<sup>2</sup>) patients present as an especially challenging surgical cohort. Only two previous studies, both utilizing the TP approach, have focused on the outcome of RARP in the morbidly obese. It has not been established if outcomes of EP-RARP in the morbidly obese differ from those of the non-morbidly obese. Herein, we sought to evaluate the perioperative and pathological outcomes associated with EP-RARP in morbidly obese men.

**Methods:** We queried our prospectively collected database (Caisis) for patients who underwent extraperitoneal robot assisted radical prostatectomy. Between July 2003 and December 2013, 1663 patients underwent EP-RARP for localized prostate cancer at our institution by a single surgeon. 40 patients were considered morbidly obese. A propensity score-matched analysis was performed using multivariate analysis incorporating 10 co-variables to identify comparable group of patients with a BMI of  $>40$  kg/m<sup>2</sup> and  $<40$  kg/m<sup>2</sup>.

**Results:** Table 1 shows that apart from BMI, the two groups were matched (all  $p$ -values  $>0.05$ ). Table 2 outlines the outcomes. Despite a higher total operating time and estimated blood loss in the morbidly obese (238 vs 176 mins,  $p < 0.0001$ , and 235 vs 192 ccs,  $p=0.003$  respectively), there were no differences in the ability to perform nerve-sparing or pelvic lymphadenectomy, or the length of stay. While the morbidly obese had a higher rate of harboring more aggressive disease on final pathology (pT3 rates 27.5 vs 7.5 % respectively), there were no differences in other postoperative pathological parameters such as prostate weight, positive surgical margin status, and Gleason score sum. Moreover, there were no differences in intra- or postoperative complications between the two groups.

**Conclusions:** EP-RARP in the morbidly obese leads to comparable perioperative and pathological outcomes to the non-morbidly obese.

## P66 WITHDRAWN

**Table 1. P65. Comparison of preoperative variables for patients undergoing RARP stratified by BMI**

Variable	Morbidly obese BMI $>40$ kg/m <sup>2</sup>	Not morbidly obese BMI $<40$ kg/m <sup>2</sup>	<i>p</i> value
Total patients, n (%)	40 (100.0)	40 (100.0)	
Mean (SD; median)			
BMI	42.9 (5.4;41.8)	29.39 (1.2; 31.8)	$<0.0001$
Age*, years	58.2 (7;59)	59 (4.2; 60)	0.54
PSA* level, ng/ml	5.5 (0.9;5.1)	5.6 (0.5; 4.2)	0.54
N (%)			
Diabetes*	14 (35)	8 (20)	0.21
Hypertension*	33 (82.5)	27 (67.5)	0.20
Coronary artery disease*	4 (10)	4 (10)	1.00
Dyslipidemia*	19 (47.5)	19 (47.5)	1.00
Prior abdominal surgery*	10 (25)	19 (47.5)	0.06
ASA	2.6 (0;3)	2.6 (1.4;3)	1.00
Preoperative Gleason score sum*			0.93
6	27 (67.5)	29 (72.5)	
7	9 (22.5)	9 (22.5)	
$\geq 8$	3 (7.5)	2 (5)	
Clinical stage*			0.53
T1	33 (82.5)	36 (90)	
T2	7 (17.5)	4 (10)	
T3	0	0	
SHIM score*			0.93
$\leq 21$	22 (55)	23 (57.5)	
$> 21$	14 (35)	17 (42.5)	

Categorical data are presented as n (%)

\* = 10 co-variables used as independent variables to base the propensity score matching

## P67 Percutaneous Nephrolithotomy in Patients with Urinary Tract Abnormalities

Philippe Violette, Marie Dion, Thomas Tailly, John Denstedt, Hassan Razvi.

Western University, London, ON, Canada.

**Background:** Patients with urinary tract abnormalities are at an increased risk of stone formation. Percutaneous nephrolithotomy (PCNL) plays an important role in the management of this patient population, however outcomes are less well defined compared to patients with normal urinary tract anatomy. Our objective was to evaluate the influence of urinary tract abnormalities on intraoperative and postoperative outcomes with PCNL.

**Methods:** We report on a single-center prospective database of 2,284 consecutive PCNL procedures in 1,935 patients from 1990 to 2012. For the purposes of this analysis, patients were categorized by the presence or absence of a urinary tract abnormality. Multivariable analyses were used to identify independent predictors of the length of hospital stay, operative time, complications and residual stones at discharge and 3 months.

**Results:** A urinary tract abnormality was present in 14.4% ( $n=330$ ) of the cohort. On univariable analysis patients with urinary tract abnormalities were more likely to present with urinary tract infection (28% vs. 19%,  $p<0.001$ ) and less likely to present with hematuria (13% vs. 19%,  $p<0.02$ ).

**Table 2. P65. Comparison of preoperative variables for patients undergoing RARP stratified by BMI**

Variable	Morbidly obese BMI >40 kg/m <sup>2</sup>	Not morbidly obese BMI <40 kg/m <sup>2</sup>	p value
Total patients, n (%)	40 (100.0)	40 (100.0)	
Mean (SD; median)			
OT, min	238(70.5; 224)	176.4(46.8; 167.5)	<0.0001
EBL	235 (70.7; 250)	192.4 (56.5; 160)	0.003
N (%)			
Nerve sparing			0.85
None	14 (35)	16 (40)	
Unilateral	11 (27.5)	9 (22.5)	
Bilateral	15 (37.5)	15 (37.5)	
PLND			0.36
Performed	18 (45)	13 (32.5)	
Not performed	22 (55)	27 (67.5)	
Mean (SD; median)			0.06
Prostate weight	61.2 (12.0; 61)	65.6 (8.4; 58.5)	
N (%)	0.36		
PSM	4 (10)	1 (2.5)	
Pathological Stage			0.04
pT2	29 (72.5)	37 (92.5)	
pT3	11 (27.5)	3 (7.5)	
Postoperative Gleason score sum			0.50
6	19 (47.5)	24 (60)	
7	19 (47.5)	14 (35)	
≥ 8	2 (5)	2 (5)	
Mean (median)	1.00		
LOS, days	1.2 (1)	1.1 (1)	

Categorical data are presented as n (%)

**Table 2. P65 (continued). Comparison of preoperative variables for patients undergoing RARP stratified by BMI**

Variable	Morbidly obese BMI >40 kg/m <sup>2</sup>	Not morbidly obese BMI <40 kg/m <sup>2</sup>	p value
N (%)			
Intraoperative complications	1.00		
None	39 (97.5)	40 (100)	
Transfusion	0		
Transient hypotension	1 (2.5)	0	
Clavien-classified complications			
Grades 1-2	1 (2.5)	0	
Grades 3-4	0	0	
Postoperative complications	0.71		
None	35 (87.5)	37 (92.5)	
Transfusion	1 (2.5)	0	
UTI	1 (2.5)	0	
Lower limb cellulitis	1 (2.5)	0	
Wound infection	1 (2.5)	0	
Bladder neck contracture	1 (2.5)	0	
Lymphocele	0	1 (2.5)	
Clot retention	0	1 (2.5)	
Urine leak	0	1 (2.5)	
Clavien-classified complications			
Grades 1-2	4 (10)	1 (2.5)	
Grades 3-4	1 (2.5)	2 (5)	

Categorical data are presented as n (%)

On multivariable regression, a urinary tract abnormality was predictive of residual stone at discharge, need for a secondary procedure, but did not increase the risk of residual stone at 3 months or the development of complications. Operative time and hospital stay were only moderately prolonged.

**Conclusions:** Patients with urinary tract abnormalities, who undergo PCNL, have a higher risk of residual stones at discharge and need for secondary procedures, but comparable complication rates, operative time and hospital stay.

## P68

### Efficacy of Tamsulosin Oxybutynin and Their Combination in the Control of Double-J Stent-related Lower Urinary Tract Symptoms

Miguel Maldonado-Avila, Rene J Jungfermann-Guzman, Leopoldo Garduño-Arteaga, Hugo A Manzanilla-García, Emmanuel Rosas-Nava, Alejandro Vela- Mollinedo, José Guzman-Esquivel, J Nestor Procuna-Hernandez, Luis Almazan-Treviño, **Marcos Del Rosario-Santiago.**

General Hospital of México, México, City, Mexico.

**Background:** Indwelling double-J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect

73-90% of patients who carry it. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin and oxybutynin and combination therapy in improving the urinary symptoms.

**Methods:** Patients who underwent ureteral stent placement after ureteroscopy (total 51), were randomized into three groups: Group I: Tamsulosin 0.4 mg once per day( 17 patients), Group II: Oxybutynin 5 mg once per day (17 patients), Group III: Tamsulosin+oxybutynin once per day (17 patients). All the groups received the medicine for three weeks and completed a Spanish validated Ureteral Stent Symptom Questionnaire (USSQ) at day 7 and 21.

**Results:** Repeated measures ANOVA showed mean urinary symptom index score was 22.3 vs. 15.5 in group three (p<0.001) at day 7 and 21 respectively. The mean work performance index was 6.6 vs 8.1 (p=0.049) favoring tamsulosin group, the mean sexual score was 0.5 vs 1.5 (p=0.03). Among additional problems the mean was 7.2 vs 6.2 (p=0.03). No significant difference was noted among pain and general health index. No side effects were reported (Table 1, Fig. 1).

**Conclusions:** Combination therapy with tamsulosin and oxybutynin improved irritative symptoms and work performance as well as sexual matters. Combination therapy should be considered for patients who complained of stent related symptoms.

**P69****Interim Results of a Randomized Trial Comparing Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi**

Kenneth Pace, Tarek Alzahrani, Daniela Ghiculete, R J D'A Honey.

St. Michaels Hospital, Toronto, ON, Canada.

**Background:** The Modulith SLX-F2 electromagnetic lithotripter (Storz Medical) is the first lithotripter on the market with a unique design allowing for a dual focus of either a narrow (6x28 mm) or wide (9x50 mm) focal zones. Ex vivo data shows that disintegration capacity and renal vascular injury are independent of the focal diameter of the SW generator at the same peak pressure and disintegration power. The objective of this study is to compare single-treatment success rates of narrow and wide focal zones for the shock wave lithotripsy (SWL) of renal stones.

**Methods:** 118 patients with a previously untreated radio-opaque solitary stone located within the kidney, measuring 5 to 15 mm in greatest diameter, were randomized to receive narrow or wide focus lithotripsy. Patients were followed with KUB x-rays and renal ultrasound at 2 and 12 weeks post lithotripsy to assess stone free status. Urinary markers indicating the degree of renal cellular damage (microalbumin and Beta-2 macroglobulin) were measured pre- and post-SWL, 24 hours post-SWL and 7 days post-treatment. Primary outcome was single-treatment success rate, defined as stone-free or adequate fragmentation (sand and asymptomatic fragments  $\leq 4\text{mm}$ ) at 3 months post-treatment.

**Results:** 61 (51.7%) patients were randomized to narrow focus lithotripsy versus 57 (48.3%) patients wide focus. The groups were similar in baseline characteristics including (age, gender, BMI, stone size and density and skin to stone distance). The overall success rates were not significantly different at 2 weeks post treatment (Narrow: 72.1% vs Wide: 61.4%;  $P=0.216$ ) nor at 3 months (Narrow: 68.3% vs Wide: 58.9%;  $P=0.292$ ). The overall complication rates was also comparable in the two groups (Narrow: 24.6% vs Wide: 17.5%;  $P=0.349$ ) including similar rates of perinephric hematoma (Narrow: 3.3% vs Wide: 3.5%;  $P=0.945$ ). The microalbumin-to-creatinine ratio was significantly different between the two groups ( $p=0.019$ ), but that difference was gone within 24 hours after the treatment.

**Conclusions:** Interim results indicated that single-treatment success rate and complications are comparable when using the narrow or wide focus of the Modulith SLX-F2. There was a difference in renal injury as measured by microalbumin to creatinine ratio (with lower values in the narrow focal zone group), but these differences disappeared within 24h of treatment. We are continuing to recruit patients to a pre-planned sample size of 300.




Fig. 1. P68.

**P70****Stone Burden Measurement by 2D or 3D Reconstruction Does Not Improve Prediction of Residual Stone at Discharge or 3 Months Compared to Standard Measurement With Elliptical Assumption**

Philippe D. Violette, Thomas Taily, Brandon R. Nadeau, Yige Bao, Justin Amann, John D. Denstedt, Hassan Razvi.

Western University, London, ON, Canada.

**Background:** Kidney stone burden has been reported as an independent predictor of postoperative outcomes of percutaneous nephrolithotomy (PCNL). By comparing different ways of quantifying stone burden, we aimed to identify/qualify which measurement of stone burden most accurately predicts those outcomes.

**Table 1. P68**

Variable		Tamsulosin	Oxybutinin	Tamsulosin + Oxybutinin	p value
Mean Urinary symptom score	Day 7	21.4 ± 4.78	22.4 ± 4.9	22.3 ± 7.2	<0.001
	Day 21	21.5 ± 6.27	17.8 ± 5.5	15.5 ± 5.0	
Mean pain index score	Day 7	13.4 ± 2.2	11.2 ± 2.7	13.8 ± 5.0	0.207
	Day 21	14.2 ± 4.3	10.9 ± 3.1	11.2 ± 5.8	
Mean general health index score	Day 7	11.7 ± 1.4	11.0 ± 1.4	11.5 ± 1.5	0.699
	Day 21	11.6 ± 1.2	11.7 ± 1.3	11.2 ± 2.5	
Mean work performance score	Day 7	6.6 ± 4.0	6.3 ± 2.5	7.0 ± 2.3	0.049*
	Day 21	8.1 ± 1.8	7.2 ± 1.9	7.7 ± 1.5	
Mean sexual matters score	Day 7	0.6 ± 1.1	0.5 ± 0.8	2.6 ± 3.8	0.036*
	Day 21	1.2 ± 1.2	1.5 ± 1.2	2.6 ± 3.8	
Mean additional problems index score	Day 7	8.05 ± 2.6	6.8 ± 1.9	7.2 ± 1.7	0.03*
	Day 21	7.4 ± 3.0	6.4 ± 1.1	6.2 ± 2.8	
Mean global USSQ	Day 7	61.9 ± 9.1	58.47 ± 8.4	64.6 ± 16.8	0.932
	Day 21	64.1 ± 12.8	55.7 ± 7.4	55.0 ± 17.7	



**Methods:** We prospectively collected data for PCNLs performed at a tertiary center between January 2006 and December 2013. A total of 246 patients had a preoperative CT and postoperative follow-up data at 3 months. Our primary outcome was incidence of residual stone at 3 months. Stone burden was measured three different methods for all patients on reformatted coronal CT images: 1) elliptical surface area (SA) (longest diameter x orthogonal diameter x  $\pi/4$ ); 2) manual outline of stone surface and computer SA calculation; 3) automatic 3D volume rendering and calculation using specific CT software (AW). SA's were described in increments 500mm<sup>2</sup>. We used logistic regression and receiver operative characteristic (ROC) curve analysis and area under the curve (AUC) to evaluate the predictive value of the three measurements.

**Results:** Our cohort had a mean age of 55.7 years, was 42.3% female and had an overall stone free rate at 3 months of 78.1%. The mean stone burden differed by method; 1) 644.3 ± 540.0 mm<sup>2</sup>; 2) 545.1 ± 404.2 mm<sup>2</sup>; 3) 9.33 ± 8.87 cm<sup>3</sup> respectively. As expected, in univariate analysis, all different methods were predictive of residual stone (OR1: 1.50, CI 1.20-1.87; OR2: 1.56, CI 1.12-2.08, OR3: 1.241, CI: 1.078-1.427 respectively). Contrary to our expectation, the AUC for the three methods of measurement were similar (0.680, 0.665 and 0.666 respectively), demonstrating equivalent predictive value.

**Conclusions:** Stone burden can be used to predict incidence of residual stone. We demonstrated that measuring the stone burden by manual outline or 3D volume assessment on reformatted NCCT images was not superior to a 2D measurement employing an elliptical assumption at predicting the incidence of residual stone.

## P71

### Mean, Range and Standard Deviation of Stone Density on Non-Contrast CT do not Predict Stone-Free Rates after Percutaneous Nephrolithotomy

Thomas Taily, Philippe D. Violette, Brandon R. Nadeau, Yige Bao, Justin Amann, John D. Denstedt, Hassan Razvi.  
Western University, London, ON, Canada.

**Background:** Stone density has been reported to influence outcomes of both extracorporeal and endoscopic stone treatment. The standard deviation (SD) of Hounsfield unit (HU) measurement of the stone has been reported to influence shockwave lithotripsy outcomes. The influence of SD or range of HU on postoperative outcomes after percutaneous nephrolithotomy (PCNL) has not been evaluated. Our objective was to identify the predictive value of stone density measurements on postoperative outcomes after PCNL.

**Methods:** We performed a retrospective chart review of prospectively collected data in a single center from January 2006 to December 2013. We identified 309 PCNL treatments that had preoperative CT for density measurements and postoperative outcome data available. CT measurements were performed by a radiologist blinded to postoperative outcomes. Mean, SD and range of HU were measured by drawing an ellipse region of interest on the stone within the borders of the stone in bone window on the CT slice portraying the largest stone diameter in axial plane. We used Logistic regression, receiver operative characteristic (ROC) curves and area under the curve (AUC) to assess their predictive value.

**Results:** Our population had an overall stone free rate (SFR) at 3 months of 78.3% and 7.8% had a second look nephroscopy. Contrary to our hypothesis, mean HU as well as SD was not found to have predictive value on SFR at 3 months. On secondary analysis, we identified mean HU by 1000 and range of HU by 100 as predictors of secondary procedure OR 2.74 (1.21, 6.20), P=0.016, and OR 1.159 (1.03, 1.30), P=0.015 respectively. Mean, SD and range of HU showed similar predictive value by ROC analysis (AUC's 0.597, 0.601 and 0.619 respectively).

**Conclusions:** In contrast to previous reports, according to our data, stone density has no predictive value on residual stone after treatment. Higher mean HU however does predict a higher chance of needing a second look nephroscopy. This preoperative assessment of stone density can be of use for surgical planning.

## P72

### Risk Factors for Re-admission Following Shock Wave Lithotripsy

Benjamin J. Nelson<sup>1</sup>, Anees Fazili<sup>1</sup>, Divya Kumar<sup>2</sup>, Franca Kraenzlin<sup>2</sup>, Jason Birnbaum<sup>2</sup>, Chang-Yong Feng<sup>1</sup>, Erdal Erturk<sup>1</sup>.

<sup>1</sup>URMC Urology, Rochester, NY, USA, <sup>2</sup>University of Rochester Medical School, Rochester, NY, USA.

**Background:** Quality improvement and pay-for-performance measures have put an increased emphasis on reducing postoperative complications and hospital re-admissions. We therefore sought to analyze the rate of re-admission and presentation to the Emergency Department (ED) within 90 days of shock wave lithotripsy (SWL), with the hope of identifying prognostic risk factors for this adverse outcome.

**Methods:** We performed a retrospective review of patients that underwent SWL therapy at our institution from 1/2011 to 5/2013 using the Storz Modulith SLX-F2 lithotripter for solitary ureteral or renal stones ≤2.0 cm. Re-admission or presentation to the ED within 90 days was our primary outcome. Secondary endpoints included stone free rates at 30 and 90 days, defined as lack of any residual fragments on follow-up KUB. Univariate and multivariate analysis were performed to identify risk factors for primary and secondary outcomes.

**Results:** Our study population included 307 patients with renal stones and 270 with ureteral stones. Mean stone size was 9.2 mm. The rate of re-admission within 90 days was 11.6%. On multivariate analysis, age, BMI, ASA score, gender, history of prior nephrolithiasis, stone location, size, and presence of a ureteral stent did not affect this outcome. Patients who underwent a non-urgent SWL, however, had a lower risk of re-admission than those who had an urgent procedure performed (OR 0.2, p = 0.0005). Among patients who were re-admitted, renal colic was the most common chief complaint (67%), followed by infection (10%) and postoperative hematoma or hematuria (7.5%). Stone free rates were 57% and 78% at 30 and 90 days, respectively. The only factors that predicted stone free rates were stone size and non-urgent SWL status.

**Conclusions:** Our rate of re-admission 90 days following SWL was 11.6%. Only the urgency of SWL was predictive of this outcome. Stone centers should monitor their re-admission rates following SWL to establish national standards and guide decision making when considering other endourologic methods if these outcomes are considered unacceptable.

## P73

### Role of Tamsulosin, Tadalafil and Silodosin As The Medical Expulsive Therapy In Lower Ureteric Stone: A Randomized Trial (A Pilot Study)

Kumar Jayant<sup>1</sup>, Santosh Kumar<sup>2</sup>, Swati Agrawal<sup>1</sup>, Mayank Mohan Agrawal<sup>2</sup>, Shrawan Kumar Singh<sup>2</sup>.

<sup>1</sup>Sudha Hospital and Medical Research Centre, Kota, India, <sup>2</sup>Postgraduate Institute of Medical Education and Research, Chandigarh, India.

**Background:** To evaluate the role of two different alpha-1 blockers and one phosphodiesterase-5 inhibitor (PDE-5) as medical expulsive therapy for distal ureteric calculi.

**Methods:** Between Jan 2011 and Dec 2012, 365 patients presenting with distal ureteric stones of size 5 to 10 mm were upon consent randomly assigned to one of three outpatient treatment arms: Tamsulosin (group A), Tadalafil (group B), Silodosin (group C). Therapy was given for a maximum of four weeks. Stone expulsion rate, time to stone expulsion, analgesic use, number of hospital visits for pain, follow-up and endoscopic treatment and adverse effects of drugs were noted. All three groups were compared for normally distributed data by analysis of variance (ANOVA), Bonferroni or Kruskal-Wallis and Mann-Whitney U tests, as required. All the classified and categorical data were analyzed for all three groups by using the chi-square test.

**Results:** There was a statistically significant expulsion rate 83.3% in group B than 64.4%, 66.7% in group A and C with lower time of stone expulsion. (p-value=0.006, p-value=0.016). Statistically significant differences were noted in colicky episodes and analgesic requirement in group B than group A and C. There was no serious adverse event.

**Conclusions:** Medical expulsive therapy for the distal ureteric stones using Tamsulosin, Silodosin and tadalafil is safe, efficacious and well tolerated.

The result of this pilot study showed that Silodosin increases ureteric stone expulsion quite significantly along with better control of pain with significantly lesser analgesic requirement.

## P74

### Outpatient Bilateral Tubeless Percutaneous Nephrolithotomy: Is it Safe?

**Michael Fuoco**, Andrea Kokorovic, James W. L. Wilson, Darren Beiko. Queen's University, Kingston, ON, Canada.

**Background:** Bilateral tubeless percutaneous nephrolithotomy (PCNL) has been reported to be safe and effective in select patients. Although outpatient PCNL has recently been shown to be safe and effective in a series of 50 patients, it requires further study before urologists embrace same day discharge following PCNL. The objective of this study is to report our early experience in performing bilateral PCNL on a completely outpatient basis, assessing its safety.

**Methods:** A review of all outpatient tubeless PCNL cases between March 2007 and May 2014 at a single Canadian centre was performed, including collection of preoperative, intraoperative and postoperative data. Strict preoperative, intraoperative and postoperative criteria were used in the selection of candidates for outpatient bilateral PCNL: no intraoperative complications including significant bleeding or collecting system perforation; postoperative hemodynamic stability; adequate pain control; and reliable patient with supportive family.

**Results:** Forty patients underwent ambulatory PCNL during the study period, of which 4 patients underwent bilateral ambulatory tubeless PCNL. Mean maximum stone diameter was 3.5 cm and 5 of the 8 renal units contained staghorn calculi. All 4 patients were discharged home on the same day with a mean hospital stay of 186 minutes or 3hrs 6 min. The mean narcotic requirement was 70.5 mg of oral morphine equivalents. Importantly, there were no postoperative complications, emergency room visits, hospital readmissions, ancillary procedures or deaths.

**Conclusions:** This small series represents the largest series of outpatient bilateral PCNL to date. In very carefully selected patients, bilateral PCNL on a completely ambulatory basis appears safe and may be feasible. Further research on outpatient bilateral PCNL is required prior to widespread adoption by urologists.

## P75

### Practice Patterns of Extracorporeal Shockwave Lithotripsy: Variability Amongst and Between Canadian and American Urologists - Do We Need Guidelines?

Andrea G. Lantz<sup>1</sup>, **Jeff P. McKay<sup>1</sup>**, Michael Ordon<sup>2</sup>, Kenneth T. Pace<sup>2</sup>, John D'A Honey<sup>2</sup>.

<sup>1</sup>Dalhousie University, Halifax, NS, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada.

**Background:** Extracorporeal shockwave lithotripsy (SWL) is a widely utilized non-invasive form of treatment for urolithiasis. Despite its widespread use, there are few evidence-based recommendations regarding pre-SWL patient work-up and performance of SWL. The purpose of this study is to determine practice patterns and to compare the performance of SWL in the United States and Canada to evaluate if there is variability between centers and countries.

**Methods:** An 18-question survey was prepared to determine pre-procedural work-up (eg: routine electrocardiograms (ECG), urine culture, discontinuation of ASA, etc) and the performance of SWL (eg: shock rate, power, stents, etc). This survey was administered in 3 phases. In Canada, SWL is a highly regionalized procedure with only 16 sites across the country. Representatives of each Canadian site were surveyed through email correspondence. The Endourology Society members were surveyed using an online survey tool, and all members of a large stone management group in the Midwest United States completed the survey. Responses across Canadian and American urologists were compared using the Chi square and Fisher's exact test.

**Results:** 16 and 187 surveys were completed from Canadian and US urologists respectively. Practice patterns varied between countries.

Specifically, routine antibiotics were more commonly given in USA (USA 78.1% vs. CAN 6.3%;  $p < 0.001$ ); a higher shock rate of 2Hz was more common in Canada (USA 16.2% vs. CAN 68.8%,  $p < 0.0001$ ); rate of discontinuing ASA for ureteral stone treatment was higher in the USA (USA 90.3% vs. CAN 50%,  $p < 0.0002$ ), and ureteral stents were more commonly used if treating a large stone in the USA (USA 88.8% vs. CAN 46.7%,  $p = 0.0002$ ). There were no significant differences between countries for use of routine pre-SWL ECG (USA 48.7% vs. CAN 43.8%,  $p = 0.71$ ), pre-SWL urine culture (USA 55.2% vs. CAN 56.3%,  $p = 0.93$ ), dose escalation (USA 87.4% vs. CAN 100%,  $p = 0.23$ ), discontinuation of ASA for renal stones (USA 95.7% vs. CAN 81.3%,  $p = 0.05$ ), and stenting for solitary kidneys (USA 66.3% vs. CAN 66.7%,  $p = 1$ ).

**Conclusions:** There are limited evidence based recommendations for the pre-procedural work-up and performance of SWL. This study highlights the lack of standardization in the performance of SWL. Significant regional differences exist in practice patterns and performance of SWL between American and Canadian urologists.

## P76

### Radiation Exposure to Surgical Staff During Percutaneous Nephrolithotomy (PCNL)-A Multi-Institutional Experience Over 12 Months

**Rick C. Slater<sup>1</sup>**, David Wenzler<sup>2</sup>, Jeannie Su<sup>2</sup>, Roger Sur<sup>2</sup>, Michelle J. Semins<sup>1</sup>.

<sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, USA, <sup>2</sup>UC San Diego, San Diego, CA, USA.

**Background:** Routine usage of fluoroscopy during endourological procedures, particularly percutaneous nephrolithotomy (PCNL), has been demonstrated to be associated with scatter radiation exposure to medical staff. Literature is sparse in reporting robust data on radiation exposure with a variety of patient demographics and procedure variables. We aim to define radiation exposure to the endourologist and their staff associated with PCNL and identify potential risk factors for higher doses.

**Methods:** Surgeons from 2 institutions prospectively collected data on a per case basis for all PCNLs during a 1 year period. Patient demographics and procedure variables recorded included patient age, body mass index (BMI), surgical duration, fluoroscopy time, and radiation exposure. Radiation exposure was recorded utilizing an instadose<sup>TM</sup> dosimeter placed on the thyroid shields of the operating surgeon, resident assistant, scrub nurse, and anesthesia staff. Associations were assessed with Spearman's (r) correlation coefficient.

**Results:** A total of 97 consecutive PCNL or second look PCNL surgeries in adult patients by 2 surgeons were evaluated over a 12 month time span (May 2013-May 2014) at two large tertiary academic medical centers. Median patient age was 53 (range 22-87) and, median BMI was 29.76 (range 16.57-55.51). Average fluoroscopy time between the two institutions was 333.53 seconds/case (Median 261, SD 301.25, range 19-1809 seconds). Average dosimeter exposure for the year was 367.5mrem, 214.5mrem, 14 mrem, and 12.5mrem while average dosimeter exposure per case was 7.65mrem, 4.42mrem, 0.28mrem, and 0.25mrem for operating surgeon, resident assistant, circulating nurse and anesthesia staff respectfully. There was a weakly positive spearman's rank correlation between fluoroscopy time and operating surgeon exposure ( $r = 0.175$ ) and BMI and operating surgeon exposure ( $r = 0.171$ ).

**Conclusions:** Radiation exposure to the operating surgeon during PCNL is not insignificant. It is important to appreciate both patient factors and procedure variables which affect this exposure. Future investigations should continue to investigate principles which help to maintain as low as reasonably achievable (ALARA) radiation exposures.

# P77

## Monotherapy With a Single Session of ESWL for Kidney Stones in the Community Setting

**Po Lam**, Brittany Paul, Christopher Pieczonka, Bashar Omarbasha, Joel Bass, Jeffrey Sekula, Elan Salzhauer, Richard Kronhaus, Andres Madissoon, Sasha Pavlov-Shapiro, Vladimir Mouraviev, David Albala. Associated Medical Professionals of NY, Syracuse, NY, USA.

**Background:** Extracorporeal shock wave lithotripsy (ESWL) has progressively acquired popularity as being the gold standard treatment for upper urinary tract urolithiasis since 1980.

**Methods:** A retrospective clinical study was performed on 2,316 patients between 2010 and 2012. Main outcome measured of our study was the clearing of stones after single session of ESWL. ESWL was done on all patients under conscious sedation by 24 board-certified urologists. The Litho Tron lithotripter (Healthtronics, Atlanta, GA) was used for the treatment. Median age of the patients was 38.7 years (range: 18-95). The percent distribution of patients according to stone size was following:  $\leq$  5mm - 15%, 5.1-10 mm- 61%, 10.1-15 mm- 15%, 15.1-20.0 mm- 7%, >20 mm-2% (Fig. 1).

**Results:** No significant perioperative complications were noted. All patients tolerated the procedure well and were discharged within 2 hours after the procedure. The results demonstrated a complete destruction of the stone in 1,488 (64.3%) cases, partial stone destruction in 496 (21.3%) and treatment failure in 331 (14.3%) patients, respectively. We found a direct correlation between large stone size and failure rate. A JJ stent was inserted before the procedure in 178 patients and after procedure in 119 patients.

**Conclusions:** No complications following ESWL treatment were noted. We conclude that ESWL remains efficacious and safe treatment modality for renal calculi in adults. Selection of patients is a crucial factor in treatment outcomes. Success rates are lower as stone size increases.




Fig. 1. P77.